Anti-HBs assays are often used to monitor the success of Hepatitis B vaccination. The presence of anti-HBs has been shown to be important in protection against Hepatitis B virus (HBV) infection. Numerous studies
have demonstrated the effectiveness of the Hepatitis B vaccine to stimulate the immune system to produce anti-HBs and to prevent HBV infection.
Assays for anti-HBs are also used to monitor the convalescence and recovery of Hepatitis B infected individuals. The presence of anti-HBs after acute HBV infection and loss of Hepatitis B virus surface antigen
(HBsAg) can be a useful indicator of disease resolution. Detection of anti-HBs in an asymptomatic individual may indicate previous exposure to HBV.
Samples with anti-HBs concentration less than 10.0 mIU/mL are considered nonreactive by the ARCHITECT Anti-HBs assay. Samples with anti-HBs concentrations greater than or equal to 10.0 mIU/mL are
Manufacturer’s reagent package insert, Architect Anti-HBs, November 2016, Abbott Ireland, Diagnostics Division Finiskin Business Park, Sligo, Ireland